Market Closed -
Nasdaq
04:00:00 2024-06-18 pm EDT
5-day change
1st Jan Change
1.93
USD
-3.50%
-11.87%
+10.28%
Cytori Therapeutics, Inc. has Changed its Name to Plus Therapeutics, Inc
July 29, 2019 at 12:00 am EDT
On July 29, 2019, Cytori Therapeutics, Inc. changed its name to Plus Therapeutics, Inc.
Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024
Jun. 07
CI
Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program
Jun. 07
MT
Plus Therapeutics, Inc. Draws $3.3 Million on Its Existing Margin Loan Facility with Pershing Llc
Jun. 04
CI
Transcript : Plus Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024
May. 15
Plus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 15
CI
Transcript : Plus Therapeutics, Inc. - Special Call
May. 09
Plus Therapeutics, Inc. acquired CNSide, a leptomeningeal metastases diagnostic platform.
May. 08
CI
Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC
May. 08
CI
Plus Therapeutics, Inc. announced that it expects to receive $6.548504 million in funding from Aigh Capital Management, LLC
May. 04
CI
Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense
Apr. 22
MT
Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense
Apr. 22
CI
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic
Mar. 25
CI
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases
Mar. 11
CI
Transcript : Plus Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Mar. 05
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 05
CI
North American Morning Briefing : S&P 500 Futures -2-
Mar. 05
DJ
Transcript : Plus Therapeutics, Inc. - Special Call
Nov. 20
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting
Nov. 20
CI
Top Premarket Gainers
Nov. 03
MT
Plus Therapeutics Shares Jump Premarket on FDA Orphan Designation
Nov. 03
DJ
Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024
23-10-31
CI
Transcript : Plus Therapeutics, Inc., Q3 2023 Earnings Call, Oct 31, 2023
23-10-31
Plus Therapeutics, Inc. announces an Equity Buyback for $0.5 million worth of its shares.
23-10-31
CI
Plus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-31
CI
Plus Therapeutics, Inc. authorizes a Buyback Plan.
23-10-30
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
More about the company
Last Close Price
1.93
USD
Average target price
19
USD
Spread / Average Target
+884.46%
Consensus
1st Jan change
Capi.
+10.28% 11.01M +34.01% 51.07B +33.84% 38.86B -8.02% 38.78B -8.98% 26.69B +12.56% 26.35B -19.62% 19.46B +39.18% 13.58B +31.47% 12.46B -3.40% 11.75B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1